Seagen Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 1998, Seagen has made significant strides in the oncology sector, particularly in the development of antibody-drug conjugates (ADCs) that target specific cancer cells while minimising damage to healthy tissue.
With a strong presence in major operational regions including North America and Europe, Seagen's core products, such as ADCETRIS and PADCEV, are recognised for their unique mechanisms of action and efficacy in treating various types of cancer. The company has established itself as a key player in the biopharmaceutical industry, achieving notable milestones such as FDA approvals and partnerships that enhance its market position. Seagen continues to drive innovation in cancer treatment, aiming to improve patient outcomes worldwide.
+60 vs industry average
Seagen Inc.’s score of 100 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Seagen Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Seagen Inc. yet.
Seagen Inc.'s reported carbon emissions
Seagen Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Pfizer Inc., and as such, it inherits emissions data and climate commitments from its parent organisation.
Seagen's climate initiatives are aligned with those of Pfizer Inc., which has set various reduction targets through the Science Based Targets initiative (SBTi) and participates in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in emissions reporting and reduction efforts.
While specific reduction targets for Seagen Inc. are not detailed, the company's commitment to sustainability is reflected in its alignment with Pfizer's broader climate strategies, including participation in initiatives like RE100 and the Race to Zero campaign.
As of now, Seagen Inc. has not publicly disclosed its own emissions figures or specific reduction commitments, but it is expected to follow the sustainability framework established by Pfizer Inc. in its ongoing efforts to address climate change.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Seagen Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Seagen Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Pfizer Inc.
Carbon Disclosure Project
Inherited from Pfizer Inc.
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Pfizer Inc.
RE 100
Inherited from Pfizer Inc.
Climate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Seagen Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project